Acknowledgement
데이터 수집에 도움을 준 차의과학대학교 하태욱학생과 이예지학생에게 감사를 드린다.
References
- Van Duijn C. Alzheimer's disease, genetic and environmental factors. Eur Psychiatry. 1998;13:217-8. https://doi.org/10.1016/S0924-9338(99)80307-1
- Service NHI. National health insurance corporation - alzheimer's (f00 and g30) treatment statistics for the number of patients and total treatment costs. Korea: Public Data Portal; 2022.
- Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with alzheimer's disease in the nursing home setting. J Am Geriatr Soc. 2001;49(12):1590-9.
- Alzforum Foundation. Therapeutics: Tacrine. 2023. Available from: https://www.alzforum.org/therapeutics/tacrine. Accessed on Oct. 30, 2023.
- FDA. Drugs@fda: Fda-approved drugs. 2021. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed on Oct. 30, 2023.
- Kim J, Lee J, Jeong JH, Kang M, Bang JS. Study of the drugs prescribed on alzheimer's disease: From the insurance claims data of korea national health insurance service. Korean J Clin Pharm. 2014;24(4):255-64.
- Huang L-K, Chao S-P, Hu C-J. Clinical trials of new drugs for alzheimer disease. J Biomed Sci. 2020;27(1):1-13. https://doi.org/10.1186/s12929-019-0592-z
- Korea Pharmaceutical Information Center. Kpic drug classification - pharmaceutical information service 2021. Available from: https://www.health.kr/searchIngredient/KPICeffect.asp. Accessed on Oct. 30, 2023.
- Zhu X-C, Tan L, Wang H-F, et al. Rate of early onset alzheimer's disease: A systematic review and meta-analysis. Ann Transl Med. 2015;3(3):38.
- Mejias-Trueba M, Perez-Moreno MA, Fernandez-Arche MA. Systematic review of the efficacy of statins for the treatment of alzheimer's disease. Clin Med. 2018;18(1):54.
- Yu J-T, Xu W, Tan C-C, et al. Evidence-based prevention of alzheimer's disease: Systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials. J Neurol Neurosurg Psychiatry. 2020;91(11):1201-9. https://doi.org/10.1136/jnnp-2019-321913
- Park H, Lee S, An S. Clinical effects of zinc supplementation in patients hospitalized with covid-19: A systematic review and meta-analysis. Korean J Clin Pharm. 2021;31(2):136-44. https://doi.org/10.24304/kjcp.2021.31.2.136
- Cochrane. Chapter 8: Assessing risk of bias in a randomized trial 2022. Available from https://training.cochrane.org/handbook/archive/v6.3/chapter-08. Accessed December 21, 2023.
- Cho, JH. Theory and Practice of Meta-Analysis. J Rhinol. 2020;27(2):83-9 https://doi.org/10.18787/jr.2020.00320
- Sperling R, Henley D, Aisen PS, et al. Findings of efficacy, safety, and biomarker outcomes of atabecestat in preclinical alzheimer disease: A truncated randomized phase 2b/3 clinical trial. JAMA Neurol. 2021;78(3):293-301. https://doi.org/10.1001/jamaneurol.2020.4857
- Cohen S, He P, Benea ML, et al. Item-level analysis of clinical measures in patients with early symptomatic alzheimer's disease following treatment with high-dose aducanumab in the phase 3 study emerge. Alzheimers Dement. 2021;17(S9):e057619.
- Budd Haeberlein S, Aisen P, Barkhof F, et al. Two randomized phase 3 studies of aducanumab in early alzheimer's disease. J Prev Alzheimers Dis. 2022;9(2):197-210. https://doi.org/10.14283/jpad.2022.30
- Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early alzheimer's disease. N Engl J Med. 2021;384(18):1691-704. https://doi.org/10.1056/NEJMoa2100708
- Ostrowitzki S, Bittner T, Sink KM, et al. Evaluating the safety and efficacy of crenezumab vs placebo in adults with early alzheimer disease: Two phase 3 randomized placebo-controlled trials. JAMA Neurol. 2022;79(11):1113-21. https://doi.org/10.1001/jamaneurol.2022.2909
- Swanson C, Dhadda S, Hodgkinson M, et al. Lecanemab, an anti-Aβ Protofibril antibody: Updated data from a randomized, double-blind phase 2b proof of concept clinical trial and open-label extension in early alzheimer's disease. J Neurol Sci. 2021;429:100.
- van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early alzheimer's disease. N Engl J Med. 2023;388(1):9-21. https://doi.org/10.1056/NEJMoa2212948
- Teng E, Manser PT, Pickthorn K, et al. Safety and efficacy of semorinemab in individuals with prodromal to mild alzheimer disease: A randomized clinical trial. JAMA Neurol. 2022;79(8):758-67. https://doi.org/10.1001/jamaneurol.2022.1375
- Xiao S, Chan P, Wang T, et al. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate alzheimer's dementia. Alzheimers Res Ther. 2021;13(1):62.
- Prins ND, Harrison JE, Chu HM, Blackburn K, Alam JJ, Scheltens P. A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild alzheimer's disease. Alzheimers Res Ther. 2021;13(1):106.
- Hirst WD, Stean TO, Rogers DC, et al. Sb-399885 is a potent, selective 5-ht6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol. 2006;553(1-3):109-19. https://doi.org/10.1016/j.ejphar.2006.09.049
- Nirogi R, Jayarajan P, Abraham R, et al. Effects of masupirdine (suvn-502) on agitation/aggression and psychosis in patients with probable alzheimer's disease: A post hoc analysis. Alzheimers Dement. 2022;18:e062695.
- Haddad HW, Malone GW, Comardelle NJ, Degueure AE, Kaye AM, Kaye AD. Aducanumab, a novel anti-amyloid monoclonal antibody, for the treatment of alzheimer's disease: A comprehensive review. Health Psychol Res. 2022;10(1):31925.
- Breijyeh Z, Karaman R. Comprehensive review on alzheimer's disease: Causes and treatment. Molecules. 2020;25(24):5789.
- Hannestad J, Duclos T, Chao W, et al. Safety and tolerability of grf6019 infusions in severe alzheimer's disease: A phase ii double-blind placebo-controlled trial. J Alzheimers Dis. 2021;81(4):1649-62. https://doi.org/10.3233/JAD-210011
- Koh SH, Kwon HS, Choi SH, et al. Efficacy and safety of gv1001 in patients with moderate-to-severe alzheimer's disease already receiving donepezil: A phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. Alzheimers Res Ther. 2021;13(1):66.
- Wang T, Kuang W, Chen W, et al. A phase ii randomized trial of sodium oligomannate in alzheimer's dementia. Alzheimers Res Ther. 2020;12(1):110.